Amplia Completes Manufacture of AMP945 for Planned Trials
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Provides Updated Investor Presentation
- Entitlement Offer Completed
- Amplia Awarded $2.1M R&D Cash Flow Loan
- App 4D and Financial Report Half Year ended 30 Sep 2021
- Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
Later from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
- AMP945 Improves Survival in Human Pancreatic Cancer Model
- Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
- Quarterly Activities and Cashflow Reports - March 2022 Qtr
- AMP945 Pre-IND Meeting Outcome
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics